March 5, 2014 / 2:55 PM / 3 years ago

FDA spurns Lilly, Boehringer diabetes drug, cites factory problem

March 5 (Reuters) - Eli Lilly and Co and partner Boehringer Ingelheim said U.S. regulators have declined to approve their experimental diabetes drug empagliflozin, citing previously observed deficiencies at a manufacturing facility where it would be made.

The drugmakers, in a joint release on Wednesday, said the U.S. Food and Drug Administration determined that deficiencies at the Boehringer Ingelheim factory would have to be resolved before the product could be approved.

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below